New York State Common Retirement Fund
CRSP icon

New York State Common Retirement Fund’s CRISPR Therapeutics CRSP Stock Holding History

New York State Common Retirement Fund’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.79M Buy
32,800
+4,800
+17% +$253K ﹤0.01% 1507
2026
Q1 		$1.33M Hold
28,000
– – ﹤0.01% 1553
2025
Q4 		$1.47M Buy
28,000
+1,800
+7% +$108K ﹤0.01% 1526
2025
Q3 		$1.7M Hold
26,200
– – ﹤0.01% 1491
2025
Q2 		$1.27M Buy
26,200
+24,972
+2,034% +$966K ﹤0.01% 1578
2025
Q1 		$41.8K Hold
1,228
– – ﹤0.01% 2839
2024
Q4 		$48.3K Hold
1,228
– – ﹤0.01% 2863
2024
Q3 		$57.7K Hold
1,228
– – ﹤0.01% 2814
2024
Q2 		$66.3K Hold
1,228
– – ﹤0.01% 3016
2024
Q1 		$83.7K Hold
1,228
– – ﹤0.01% 2817
2023
Q4 		$76.9K Buy
+1,228
New +$67.9K ﹤0.01% 2845
2022
Q2 		– Sell
-5,934
Closed -$372K – 3484
2022
Q1 		$372K Buy
5,934
+2,000
+51% +$126K ﹤0.01% 2536
2021
Q4 		$298K Buy
3,934
+150
+4% +$13.1K ﹤0.01% 2711
2021
Q3 		$424K Hold
3,784
– – ﹤0.01% 2551
2021
Q2 		$613K Sell
3,784
-1,050
-22% -$128K ﹤0.01% 2486
2021
Q1 		$589K Sell
4,834
-3,010
-38% -$454K ﹤0.01% 2373
2020
Q4 		$1.2M Buy
7,844
+5,210
+198% +$616K ﹤0.01% 1959
2020
Q3 		$220K Hold
2,634
– – ﹤0.01% 2604
2020
Q2 		$194K Hold
2,634
– – ﹤0.01% 2653
2020
Q1 		$112K Sell
2,634
-3,011
-53% -$155K ﹤0.01% 2715
2019
Q4 		$344K Buy
5,645
+3,061
+118% +$167K ﹤0.01% 2470
2019
Q3 		$106K Buy
2,584
+450
+21% +$21.5K ﹤0.01% 3012
2019
Q2 		$101K Sell
2,134
-200
-9% -$7.99K ﹤0.01% 3102
2019
Q1 		$83K Sell
2,334
-150
-6% -$5.19K ﹤0.01% 2997
2018
Q4 		$71K Sell
2,484
-4,619
-65% -$161K ﹤0.01% 3043
2018
Q3 		$315K Sell
7,103
-2,488
-26% -$130K ﹤0.01% 2628
2018
Q2 		$564K Sell
9,591
-100
-1% -$5.7K ﹤0.01% 2398
2018
Q1 		$443K Buy
9,691
+1,107
+13% +$45.7K ﹤0.01% 2409
2017
Q4 		$202K Sell
8,584
-10,692
-55% -$203K ﹤0.01% 2754
2017
Q3 		$344K Buy
+19,276
New +$350K ﹤0.01% 2536

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

New York State Common Retirement Fund's CRSP Position: Q2 2026 in Review

New York State Common Retirement Fund increased its CRISPR Therapeutics (CRSP) stake by 17% in Q2 2026, buying an estimated $253K and bringing the position to 32,800 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1507.

New York State Common Retirement Fund first reported a position in CRSP in Q3 2017 and has held it in 30 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • New York State Common Retirement Fund held 32,800 shares of CRISPR Therapeutics worth $1.79M as of Q2 2026.
  • New York State Common Retirement Fund bought 4,800 CRISPR Therapeutics shares in Q2 2026, an estimated $253K.
  • CRISPR Therapeutics made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #1507 holding.
  • New York State Common Retirement Fund first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 30 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.